Albumin and Uptake of Drugs in Cells: Additional Validation Exercises of a Recently Published Equation that Quantifies the Albumin-Facilitated Uptake Mechanism(s) in Physiologically Based Pharmacokinetic and Pharmacodynamic Modeling Research

Journal of Pharmaceutical Sciences

Volumn 104, Issue 12, 2015, Pages 4448-4458

  Poulin, Patrick ^a,b   Haddad, Sami ^b  

^a Consultant ^*  (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

ADME; clearance; disposition; drug safety; hepatocytes; isolated perfused liver; IVIVEs; pharmacodynamics; pharmacokinetics; PKPD

Indexed keywords

ALBUMIN; BOSENTAN; DRUG; MIBEFRADIL; MIDAZOLAM; OXAZEPAM; RIFAMPICIN; TAUROCHOLIC ACID; WARFARIN; ALBUMINOID; PROTEIN BINDING;

ARTICLE; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG UPTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; KINETIC PARAMETERS; LIVER CELL; LIVER PERFUSION; MATHEMATICAL MODEL; PREDICTIVE VALUE; PROTEIN BINDING; UNBOUND FRACTION; VALIDATION STUDY; VALIDITY; ANIMAL; CELL CULTURE; DOG; MDCK CELL LINE; METABOLISM; PHYSIOLOGY; RAT;

ALBUMINS; ANIMALS; CELLS, CULTURED; DOGS; HEPATOCYTES; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; RATS;

EID: 84954404629     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24676     Document Type: Article

References (44)

1. Poulin P, Burczynski FJ, Haddad S,. 2015. The role of extracellular binding proteins in the cellular uptake of drugs: Impact on quantitative in vitro-to-in vivo extrapolations of toxicity and efficacy in physiologically based pharmacokinetic-pharmacodynamic research. J Pharm Sci.104 [Epub ahead of print]
2. Francis FL,. 2010. Albumin and mammalian cell culture: Implications for biotechnology applications. Cytotechnology 62: 1-16.
3. Mizuma T, Horie T, Shui A,. 1985. The effect of albumin in the uptake of bromosulfopthalein by isolated rat hepatocytes. J Pharmacobiodyn 8: 90-94.
4. Tsao SC, Sugiyama Y, Shinmura K, Sawada Y, Nagase S, Iqa T, Hanano M,. 1988. Protein mediated hepatic uptake of rose bengal in analbuminemic mutant rat NAR. Albumin is not indispensable to the protein-mediated transport of rose bengal. Drug Metab Dispos 16: 482-489.
5. Forker EL, Luxon BA,. 1983. Albumin mediated transport of rose Bengal by perfused rat liver. J Clin Investig 72: 1764-1771.
6. Tsao SC, Sugiyama Y, Sawada Y, Nagase S, Iga T, Hanano M,. 1986. Effect of albumin on hepatic uptake of warfarin in normal and analbuminemic mutant rats: Analysis by multiple indicator dilution method. J Pharmacokinet Biopharm 14: 51-64.
7. Tsao SC, Sugiyama Y, Sawada Y, Iga T, Hanano M,. 1988. Kinetic analysis of albumin-mediated uptake of warfarin by perfused rat liver. J Pharmacokinet Biopharm 16: 165-181.
8. Forker EL, Luxon BA,. 1981. Albumin helps mediate removal of Taurocholate by rat liver. Am J Physiol 67: 1517-1522.
9. Blanchard N, Hewitt NJ, Silber P, Jones H, Coassolo P, Lavé T,. 2006. Prediction of hepatic clearance using cryopreserved human hepatocytes: A comparison of serum and serum free incubations. J Pharm Pharmacol 58: 633-641.
10. Iwatsubo T, Hirota N, Ooie T, Suziki H, Sugiyama Y,. 1996. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopham Drug Dispos 17: 273-310.
11. Bounakta S, Haddad S,. 2015. Study of Bisphenol A and naproxen metabolic interactions in isolated perfused rat liver. Toxicol Sci 144 (1):Abstract #1383.
12. Besseghir K, Mosig D, Roch-Ramel, F,. 1989. Facilitation by serum albumin of renal tubular secretion of organic anions. Am J Physiol 256: F475-F484.
13. Taft DR, Sweeney KR,. 1995. The influence of protein binding on the elimination of acetazolamide by the isolated perfused rat kidney: Evidence of albumin-mediated tubular secretion. J Pharmacol Exp Ther 274: 752-760.
14. Jahic M, Baik J, Li CM, Jiang W, Zhang X, Warren MS, Huang Y,. 2015. Should total plasma drug concentration be used to predict transporter mediated drug-drug interactions for highly protein bound drugs ? Poster # P164, 13th European ISSX Meeting, Glasgow, UK.
15. Ge G, Ai CZ, Hu WB, Hou J, Zhu LL, He GY, Fang ZZ, Liang SC, Wang FY, Yang L,. 2013. The role of serum albumin in the metabolism of Boc5: Molecular identification, species differences and contribution to plasma metabolism. Eur J Pharm Sci 48: 360-369.
16. Mao J, Johnson TR, Shen Z, Yamazaki S,. 2013. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: Comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos 41: 343-352.
17. Poulin P, Kenny JR, Hop CE, Haddad S,. 2012. In vitro-in vivo extrapolation of clearance: Modeling hepatic metabolic clearance of highly bound drugs and comparative assessment with existing calculation methods. J Pharm Sci 101: 838-851.
18. Poulin P, Hop CE, Haddad S, Kenny JT,. 2012. Comparative assessment of in vitro-in vivo extrapolation methods used for predicting hepatic metabolic clearance of drugs. J Pharm Sci 101: 4308-4326.
19. Poulin P, Haddad S,. 2013. Toward a new paradigm for the efficient in vitro-in vivo extrapolation of metabolic clearance in humans from hepatocyte data. J Pharm Sci 102: 3239-3251.
20. Poulin P,. 2013. Prediction of total hepatic clearance by combining metabolism, transport, and permeability data in the in vitro-in vivo extrapolation methods: Emphasis on an apparent fraction unbound in liver for drugs. J Pharm Sci 102: 2085-2095.
21. Burczynski FJ, Wang GQ, Elmhadoun B, She YM, Roberts MS, Standing KG,. 2001. Hepatocyte palmitate uptake: Effect of albumin surface charge modification. Can J Physiol Pharmacol 79: 868-875.
22. Ghosh A, Maurer TS, Litchfield J, Varma MV, Rotter C, Scialis R, Feng B, Tu M, Guimaraes CR, Scott DO,. 2014. Toward a unified model of passive drug permeation II: The physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators. Drug Metab Dispos 42: 1599-1610.
23. Heuberger J, Schmidt S, Derendorf H,. 2013. When is protein binding important? J Pharm Sci 102: 3458-3467.
24. Rodgers T, Rowland M,. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95: 1238-1257.
25. Peyret T, Poulin P, Krishnan K,. 2011. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals. Toxicol Appl Pharmacol 249: 197-207.
26. Poulin P, Chen YH, Ding X, Gould SE, Hop ECJ, Messick K, Oeh J, Liederer B,. 2015. Prediction of drug distribution in subcutaneous xenografts of human tumor cell lines and healthy tissues in mouse: Application of the tissue composition-based model to antineoplastic drugs. J Pharm Sci 104: 1508-1521.
27. Poulin P,. 2015. Drug distribution to human tissues: Prediction and examination of the basic assumption in in vivo pharmacokinetics-pharmacodynamics (PK/PD) research. J Pharm Sci 104: 2110-2118.
28. Batistela VR, Pellosi DS, de Souzaa FD, de Costa WF, de Oliveira Santin SM, de Souza VR, Caetano W, de Oliveira HP, Scarminio IS, Hioka N,. 2011. pKa determinations of xanthene derivates in aqueous solutions by multivariate analysis applied to UV-Vis spectrophotometric data. Spectrochimica Acta A Mol Biomol Spectrosc 79: 889-897.
29. Santa Cruz Biotechnology, Inc. 2015. Sodium taurocholate. Material safety datasheet.
30. Song IH, Borland J, Savina PM, Chen S, Patel P, Wajima T, Peppercorn AF, Piscitelli SC,. 2013. Pharmacokinetics of single-dose dolutegravir in HIV-seronegative subjects with moderate hepatic impairment compared to healthy matched controls. Clin Pharmacol Drug Dev 2: 342-348.
31. Boman G, Ringberger VA,. 1974. Binding of rifampicin by human plasma proteins. Eur J Clin Pharmacol 7: 369-373.
32. Food and Drug Administration. 2012. Clinical pharmacology and biopharmaceutic reviews of Bosentan. NDA Number 21-290.
33. Ménochet K, Kenworthy KE, Houston JB, Galetin A,. 2012. Simultaneous assessment of uptake and metabolism in rat hepatocytes: A comprehensive mechanistic model. J Pharmacol Exp Ther 341: 2-15.
34. Fitz JG, Lidofsky SD, Xie MH, Scharschmidt BF,. 1992. Transmembrane electrical potential difference regulates Na+/HCO3-cotransport and intracellular pH in hepatocytes. Proc Natl Acad Sci 89: 4197-4201.
35. Partition coefficient-Log D of rifampicin. Accessed 31 August, 2015, at: www.cerep.com.
36. Watson VM,. 2014. The clinical pharmacology of human immunodeficiency virus (HIV) therapy failure. PhD thesis, University of Liverpool, United Kingdom.
37. Australian Government, Department of Health. 2004. Australian Public Assessment Report for Dolutegravir (as sodium). Therapeutic goods administration. www.tga.gov.au/auspar/auspar-dolutegravir-sodium. Last accessed 2 October, 2015.
38. Food and Drug Administration. 2012. Clinical pharmacology review of dolutegravir. Reference ID: 3310563.
39. Poulin P, Theil FP,. 2009. Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. J Pharm Sci 98: 4941-4961.
40. Cui Y, Walter B,. 2003. Influence of albumin binding on the substrate transport mediated by human hepatocyte transporters OATP2 and OATP8. J Gastroenterol 38: 60-68.
41. van Montfoort JE, Hagenbuch B, Fattinger KE, Müller M, Groothuis GM, Meijer DK, Meier PJ,. 1999. Polyspecific organic anion transporting polypeptides mediate hepatic uptake of amphipathic type II organic cations. J Pharmacol Exp Ther 291: 147-152.
42. Roth M, Obaida A, Hagenbuch B,. 2012. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 165: 1260-1287.
43. Moaddel R, Ravichandran S, Bighi F, Yamaguchi R, Wainer IW,. 2007. Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Br J Pharmacol 151: 1305-1314.
44. Poulin P,. 2015. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: Rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design. J Pharm Sci 104: 2359-2368